Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Taiwan Advance Bio-Pharmaceutical had a gross margin of 66.36% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Taiwan Advance Bio-Pharmaceutical Gross Margin % Related Terms
Taiwan Advance Bio-Pharmaceutical Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4186 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advance Bio-Pharmaceutical Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a Gross Margin % of 66.36% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. This is 21% above median its historical median of 54.71. Over the past decade, Taiwan Advance Bio-Pharmaceutical's Gross Margin % has ranged from 49.77 to 68.88. According to the industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #337 out of 732 companies in the Biotechnology industry, placing it in the top 46%.
Is Taiwan Advance Bio-Pharmaceutical's Gross Margin % too high?
Taiwan Advance Bio-Pharmaceutical's current Gross Margin % of 66.36% is 21% above median its 10-year median of 54.71. Over the past 10 years, this metric has ranged from a low of 49.77 to a high of 68.88. The Biotechnology industry median Gross Margin % is 60.91. Taiwan Advance Bio-Pharmaceutical's value of 66.36% is 8.9% above this industry median. Based on the distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #337 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #337 out of 732 companies for Gross Margin %. This puts Taiwan Advance Bio-Pharmaceutical in the upper half of its industry. The industry median Gross Margin % is 60.91. Taiwan Advance Bio-Pharmaceutical's value of 66.36% is 8.9% above this benchmark. Historically, Taiwan Advance Bio-Pharmaceutical's own Gross Margin % has ranged from 49.77 to 68.88 over the past decade. While the company's 10-year median is 54.71 vs. the industry median of 60.91, Taiwan Advance Bio-Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Advance Bio-Pharmaceutical's current Gross Margin % of 66.36% is 8.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advance Bio-Pharmaceutical's current Gross Margin % is 66.36%, which is 21% above median its own 10-year median of 54.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.88, compared to a current price of NT$10.10 — trading 43.5% below its estimated fair value. The current Gross Margin % is 66.36%, which is 21% above median its 10-year median of 54.71 and 8.9% above the Biotechnology industry median of 60.91. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current Gross Margin % is 66.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued.
The current stock price of NT$10.10 is trading 43.5% below its estimated GF Value™ of NT$17.88.
GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:4186:
Gross Margin %: 66.36% (21% above median its 10-year median of 54.71)
GF Value™: NT$17.88 vs. price of NT$10.10 (43.5% below fair value)
Industry Position: 8.9% above the Biotechnology median (#337 of 732)
No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advance Bio-Pharmaceutical Business Description
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
52GF Score
Get the complete analysis for ROCO:4186
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4186 has been successfully added to your 
